Berberine has direct antimicrobial effects against gram-positive and gram-negative bacteria, often used as natural alternative to rifaximin for SIBO.

This guide covers the underlying mechanism, the human and animal evidence supporting berberine for small intestinal bacterial overgrowth (SIBO), a practical dosing protocol, and the products that consistently appear in evidence-based stacks.

Berberine is an isoquinoline alkaloid extracted from plants in the Berberis family (barberry), as well as Coptis chinensis (goldthread), Hydrastis canadensis (goldenseal), Mahonia aquifolium (Oregon grape), and Phellodendron amurense. It has been used in Traditional Chinese Medicine and Ayurveda for >2,500 years for digestive infections; modern research has revealed potent metabolic effects.

Berberine's primary mechanism is activation of AMPK (AMP-activated protein kinase) — the same "metabolic master switch" activated by metformin, exercise, and caloric restriction. AMPK shifts cells toward catabolism: increased glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and reduced lipogenesis. Berberine also inhibits PCSK9 (lowers LDL), modulates the gut microbiome, inhibits DPP-4 (the enzyme GLP-1 inhibitors target), and has direct insulin-sensitizing effects on muscle and adipose tissue.

Bioavailability is the key clinical limitation. Standard berberine HCl has only ~5% oral bioavailability — most is excreted unchanged. This is why standard dosing is 500 mg three times per day with meals (1500 mg total) rather than once daily. Newer formulations — dihydroberberine (a reduced metabolite with ~5× higher bioavailability), berberine phytosome (Berberine Phytosome by Indena, complexed with phosphatidylcholine), and liposomal berberine — achieve equivalent effects at lower doses with less GI upset.